Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Mannequinon Mar 28, 2024 4:23pm
53 Views
Post# 35958994

RE:RE:RE:Selling Sort1 Platform

RE:RE:RE:Selling Sort1 Platform

I disagree with that approach to monetization.  One single payment can spool up an entire R&D lab which could be further funded by other partnerships. I'm surprised you don't see that. 


palinc2000 wrote:

THTX does not have the financial means nor the expertise to carry this program ...
If they are able to find a buyer and get an upfront payment and milestone payments and a double digit royalty that would be FANTASTIC
Surprising that you cant see that
 


Mannequin wrote: I invested in the program and company not to just save their jobs so that they can sell it. That would be the only way they would ever do it. So that Paul can make his $2 million per year while somebody else gets rich if it works. If it doesn't work, they can dial it down, cut costs and still make money. Selling it would be ridiculous. 

 


 

<< Previous
Bullboard Posts
Next >>